Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 20/20 | 0.69 |
| ▸ | PDGFRB | P09619 | 9/20 | 0.52 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL835030 | 0.91 | KDR (0.83) | KDRPDGFRBEIF2AK2 | |
| SCHEMBL848188 | 0.91 | KDR (0.83) | KDRPDGFRBEIF2AK2 | |
| SCHEMBL10182233 | 0.89 | KDR (0.54) | KDRPDGFRB | |
| SCHEMBL10182337 | 0.88 | KDR (0.63) | KDRPDGFRBEIF2AK2 | |
| SCHEMBL10182051 | 0.86 | KDR (0.51) | KDRPDGFRBEIF2AK2 | |
| SCHEMBL10182158 | 0.86 | KDR (0.65) | KDRPDGFRBEIF2AK2 | |
| SCHEMBL834629 | 0.85 | KDR (0.75) | KDRPDGFRBEIF2AK2 | |
| SCHEMBL848398 | 0.85 | KDR (0.75) | KDRPDGFRBEIF2AK2 | |
| SCHEMBL869778 | 0.85 | KDR (0.55) | KDRPDGFRBEIF2AK2 | |
| SCHEMBL10183847 | 0.84 | KDR (0.54) | KDRPDGFRBEIF2AK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383825-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120207810-A1 | Kinase Inhibitors | SPADA LON T (US) | 2012-08-16 | — | — | US | disclosed |
| US-8143410-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110263611-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20100278897-A1 | INTRAOCULAR BIOACTIVE AGENT DELIVERY SYSTEM WITH MOLECULAR PARTITIONING SYSTEM | ALLERGAN, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20090196906-A1 | Kinase inhibitors | ALLERGAN, INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263611-A1 | Kinase Inhibitors | PTK2, MAP3K6, MAP3K20 | KDR 51/4885PDGFRB 368/4885EIF2AK2 882/4885 |
| US-20120207810-A1 | Kinase Inhibitors | PTK2, MAP3K6, MAP3K20 | KDR 51/4885PDGFRB 368/4885EIF2AK2 882/4885 |
| US-20100278897-A1 | INTRAOCULAR BIOACTIVE AGENT DELIVERY SYSTEM WITH MOLECULAR PARTITIONING SYSTEM | MMP1, IGFBP2, BMP2 | KDR 570/4885PDGFRB 1150/4885EIF2AK2 1387/4885 |
| US-20090196906-A1 | Kinase inhibitors | PTK2, MAP3K6, MAP3K20 | KDR 51/4885PDGFRB 368/4885EIF2AK2 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.